Content Type: Article

  • COVID-19 – Economic Stabilization Fund in Germany

    ARTICLE / CLIENT ALERT

    COVID-19 – Economic Stabilization Fund in Germany

    March 26, 2020

    Read time: 2 min

    Key takeaways
    Overview

    As part of the Coronavirus (COVID-19) legislative aid program, the German Federal Government released a draft legislative proposal for the establishment of an economic stabilization fund (Wirtschaftsstabilisierungsfonds) in the total amount of EUR 600 billion to mitigate the economic consequences caused by the Coronavirus and stabilize German companies that have a significant impact on the German economy in terms of employees, turnover and/or balance sheet total. This law allows the Federal Republic to provide aid to companies in crisis in the form of guarantees or direct recapitalization measures.

    Read full article in German here.

    In depth
    Authors
    More insights

  • Schedule 13G: Coronavirus Update for Private Fund Managers — SEC Extends Limited Filing Relief for Schedule 13G Filers

    Schedule 13G: Coronavirus Update for Private Fund Managers — SEC Extends Limited Filing Relief for Schedule 13G Filers

    ARTICLE / CLIENT ALERT

    Schedule 13G: Coronavirus Update for Private Fund Managers — SEC Extends Limited Filing Relief for Schedule 13G Filers

    March 26, 2020

    Read time: 4 min

    Key takeaways
    Overview

    As previously discussed in our March 15, 2020 SRZ Alert, on March 4, 2020, the U.S. Securities and Exchange Commission, under the “public interest” powers in Section 36 of the Securities Exchange Act of 1934, as amended, (“Exchange Act”) issued an order[1] providing conditional regulatory relief to SEC registrants subject to the reporting requirements of the Exchange Act and other persons required to make filings under the Exchange Act that are unable to make certain filings in a timely manner due to circumstances related to COVID-19. The order included relief for filers required to file on Schedule 13G between March 1, 2020 and April 30, 2020. On March 25, 2020, the SEC issued an order[2] superseding the original order which expanded the period covered by the order to March 1, 2020 to July 1, 2020.

    The criteria and requirements for relying on the relief remain the same. Schedule 13G filers that are unable to meet the filing deadline or amendment deadline falling during the period of relief due to circumstances related to COVID-19:

    • Will have an additional 45 days past the due date to file the applicable Schedule 13G or amendment filing; and
    • Any Schedule 13G filer relying on the order must disclose when it files the applicable Schedule 13G or amendment that it relied on the order and state why it could not file the schedule on time.

    As a practical matter, the relief is not likely to be relevant to registered investment advisers or other registered institutions filing Schedule 13G under Rule 13d-1(b), since they are not generally required to make an initial Schedule 13G filing until 45 days after year end. Given the current period covered by the order, the relief is only applicable to Schedule 13G filers that file under Rule 13d-1(c) and are required to make their initial Schedule 13G filings within 10 days of their beneficial ownership exceeding 5% and required to amend “promptly” after crossing 10% (and thereafter “promptly” upon increasing or decreasing their beneficial ownership by 5%) or Rule 13d-1(b) filers require to amend their Schedule 13G filings or accelerate their initial filing, as applicable, within 10 days of the end of the month in which their beneficial ownership exceeds 10% as of month end (and thereafter, within 10 days after the end of the month that their beneficial ownership increases or decreases by 5% as of month end).

    The relief continues to exclude Schedule 13D filings, amendments to Schedule 13D filings and Section 16 filings (Form 3 and Form 4).

    Authored by Eleazer Klein and Adriana Schwartz.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] Order Under Section 36 of the Securities Exchange Act of 1934 Granting Exemptions From Specified Provisions of the Exchange Act and Certain Rules Thereunder, Release No. 34-88318 (March 4, 2020), available here.

    [2] Order Under Section 36 of the Securities Exchange Act of 1934 Modifying Exemptions From the Reporting and Proxy Delivery Requirements for Public Companies, Release No. 34-88465 (March 25, 2020), available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Ele Klein

    Partner

    New York – 919 Third Avenue

    More insights

  • SEC Update: Staff Guidance on Manual Signatures of EDGAR Filings

    SEC Update: Staff Guidance on Manual Signatures of EDGAR Filings

    ARTICLE / CLIENT ALERT

    SEC Update: Staff Guidance on Manual Signatures of EDGAR Filings

    March 26, 2020

    Read time: 4 min

    Key takeaways
    Overview

    On March 24, 2020, the staff of the Division of Corporation Finance, the Division of Investment Management and the Division of Trading and Markets of the U.S. Securities and Exchange Commission issued a staff statement addressing authentication document retention requirements under Rule 302(b) of Regulation S-T, in light of the current COVID-19 outbreak.[1] Regulation S-T contains rules prescribing requirements for making filings electronically with the SEC through its Electronic Data Gathering, Analysis, and Retrieval system (“EDGAR”). Rule 302(b) under Regulation S-T requires that a signatory to documents that are electronically filed with the SEC “manually sign a signature page or other document authenticating, acknowledging or otherwise adopting his or her signature that appears in typed form within the electronic filing.”[2] In addition, the signatory must execute the document prior to the submission of the electronic filing to the SEC, and such physical document must be retained by the filer for a period of five years.[3]

    The staff statement notes that, due to the COVID-19 situation, persons and entities subject to the authentication document retention requirements may encounter difficulties in complying with such requirements. In particular, given the logistical difficulties presented by the COVID-19 situation with respect to satisfaction of the Rule 302(b) requirements, including the requirement that each signatory provide the signature page to the filer, the staff statement provides assurances that the staff will not recommend an enforcement action if:

    • A signatory retains a manually signed signature page or other document authenticating, acknowledging or otherwise adopting their signature that appears in typed form in the electronic filing, and they provide the document to the filer for retention as soon as reasonably practicable;
    • The manually signed or authenticated document indicates the date and time that the signature was executed; and
    • The filer establishes and maintains policies and procedures governing this process.

    The staff statement also indicates that a signatory may wish to provide the filer with an electronic record of the signed document (such as a photograph or PDF of the manual signature).

    In view of the current COVID-19 situation, those subject to the requirements of Rule 302(b) must consider implementing policies and procedures for the collection of manual signature images or pdfs, as well as the collection and retention of executed signature pages or documents. For assistance with developing policies and procedures to comply with Rule 302(b) and the staff statement, or if you have any questions about the content of this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors. 

    Authored by Karen Spiegel and Noah B. Aschen.


    [1] Staff statement Regarding Rule 302(b) of Regulation S-T in Light of COVID-19 Concerns (March 24, 2020), available here.

    [2] 17 CFR § 232.302(b).

    [3] Id.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • OCR Issues Guidance Regarding COVID-19, HIPAA, and Disclosures to First Responders and Public Health Authorities

    ARTICLE / CLIENT ALERT

    OCR Issues Guidance Regarding COVID-19, HIPAA, and Disclosures to First Responders and Public Health Authorities

    March 25, 2020

    Read time: 2 min

    Key takeaways
    Overview

    The US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) issued additional guidance today, March 25, 2020,  regarding disclosures of protected health information (PHI) to law enforcement, paramedics, other first responders and public health authorities in the context of the Coronavirus (COVID-19) global pandemic. Specifically, OCR has reiterated that the HIPAA Privacy Rule permits a covered entity to disclose, under certain circumstances, the name or other identifying information of an individual who has been infected with, or exposed to, the virus SARS-CoV-2, or the disease caused by the virus, COVID-19, with law enforcement, paramedics, other first responders and public health authorities without the individual’s authorization. The guidance discusses specific examples such of permitted disclosures, ranging from disclosures that are required by law pursuant to infectious disease reporting requirements to disclosures by healthcare providers in prison medical facilities to correctional officers at the facility. The guidance is available online and can be viewed here.

    In depth
    Authors

    Ryan S. Higgins

    Partner

    Chicago

    More insights

  • OIG Clarifies Scope of Telehealth Copayment Waiver

    ARTICLE / CLIENT ALERT

    OIG Clarifies Scope of Telehealth Copayment Waiver

    March 25, 2020

    Read time: 4 min

    Key takeaways
    Overview

    On March 24, 2020, the US Department of Health and Humans Services Office of Inspector General (OIG) issued guidance regarding OIG’s March 17, 2020, policy statement on reductions or waivers of cost-sharing obligations owed by federal healthcare program beneficiaries for telehealth services. While the original policy statement set conditions which, if met by physicians or practitioners, would allow them to avoid administrative sanctions for granting such reductions or waivers, the March 24 guidance clarifies OIG’s position on the scope of telehealth services covered.

    In depth

    On March 24, 2020, the US Department of Health and Human Services Office of Inspector General (OIG) issued guidance (Guidance) regarding the policy statement permitting routine waiver of copays for telehealth services (Policy Statement) issued on March 17, 2020. The Guidance clarifies the scope of “telehealth services” that may be the subject of the copayment waivers and clarifies the type of providers to which the Policy Statement applies.

    Through the Policy Statement, OIG notified physicians and other practitioners that they will not be subject to administrative sanctions for reducing or waiving any cost-sharing obligations that federal healthcare program beneficiaries may owe for telehealth services for arrangements that satisfy both of the following conditions:

    1. A physician or other practitioner reduces or waives cost-sharing obligations (i.e., coinsurance and deductibles) that a beneficiary may owe for telehealth services furnished consistent with the then-applicable coverage and payment rules.
    2. The telehealth services are furnished during the time period subject to the COVID-19 national emergency declaration.

    OIG will not view the provision of free telehealth services alone as an inducement or as likely to influence future referrals (i.e., OIG will not view the furnishing of subsequent services occurring as a result of the free telehealth services, without more, as evidence of an inducement) for any free telehealth services furnished during the pendency of the emergency declaration. The Policy Statement, however, did not define the scope of the “telehealth services” subject to the waiver.

    The Guidance clarifies OIG’s position on the scope of “telehealth services,” stating that such services are not limited to the narrow set of services referred to by the Centers for Medicare and Medicaid Services (CMS) as “telehealth visits” under the Medicare Part B program. Rather, OIG reported that it intends for the Policy Statement to apply more broadly to “non-face-to-face services furnished through various modalities, including telehealth visits, virtual check-in services, e-visits, monthly remote care management, and monthly remote patient monitoring.”

    In addition, OIG clarified that the availability of the waivers is not limited to physicians and other practitioners who bill for their services; the availability of waivers also extends to hospitals or other eligible individuals or entities that bill on behalf of the physician or practitioner pursuant to a reassignment of his or her right to receive payments to such individual or entity.

    This clarification should be welcome to physicians, hospitals and health systems that are seeking alternatives to in-person patient visits and ways to alleviate the financial burden of such services for certain patient populations during the COVID-19 national emergency. However, as noted in our discussion regarding COVID-19 beneficiary inducement questions, certain other considerations might be at play when evaluating copay waivers that would apply to the still fairly narrow contours of OIG’s telehealth

    Authors

    Amanda Enyeart

    Partner

    Chicago

    More insights

  • Key COVID-19 Developments and Guidance for Ambulatory Surgery Centers

    Key COVID-19 Developments and Guidance for Ambulatory Surgery Centers

    ARTICLE / CLIENT ALERT

    Key COVID-19 Developments and Guidance for Ambulatory Surgery Centers

    March 25, 2020

    Read time: 9 min

    Key takeaways
    Overview

    As the Coronavirus (COVID-19) pandemic continues to impact the healthcare industry and the global economy, ambulatory surgery centers (ASCs) should be mindful of federal and state guidance impacting their daily work and revenue streams, employee activities and offering potential avenues for financial relief. This On the Subject summarizes key guidance and recommendations for ASCs navigating these unprecendented challenges.

    In depth

    Elective Surgeries and Procedures and COVID-19 Response Support

    • Elective Surgeries and Procedures. On March 18, 2020, the Centers for Medicare & Medicaid Services (CMS) recommended that all non-essential procedures be postponed until further notice. While CMS recommendations are not yet mandatory, several states have mandated that elective surgeries and procedures be postponed. Additional states are likely to take similar actions as the Coronavirus (COVID-19) pandemic continues to stress the healthcare system throughout the country.
    • ASCA Guidance. On March 19, 2020, the Ambulatory Surgery Center Association (ASCA) released new guidance for ambulatory surgery centers (ASCs) with respect to what might constitute a “necessary surgery” during the COVID-19 pandemic. The guidance states that “[a] surgery may be deemed urgent and necessary if the treating physician decides that a months-long delay would increase the likelihood of significantly worse morbidity or prognosis for the patient,” and provides examples of cases that might need to proceed with surgery during the COVID-19 pandemic.

    The ASCA noted that ASCs should be prepared in case hospitals need to shift necessary surgeries to ASCs or ASC resources otherwise become necessary to support community efforts to address the COVID-19 pandemic. The ASCA cautioned that the effects of the pandemic could create situations in which ASCs must temporarily suspend services, such as when an individual who has been in an ASC facility is suspected or diagnosed with COVID-19, or when a significant shortage of personal protective equipment prevents the safe practice of surgical cases. ASCA is also tracking state activity affecting ASCs.

    On March 20, 2020, the ASCA released a message to ASCs instructing them to strictly adhere to federal and state guidance to immediately postpone all surgeries that can be delayed for six to eight weeks and to use personal protective equipment sparsely and wisely. The ASCA encouraged all ASCs to communicate with their local hospitals to ensure a coordinated response in the best interest of their communities.

    The ASCA also released a checklist for ASCs to be prepared to share essential information about the resources and capacity they can contribute to a community-wide COVID-19 response.

    Financial and Employee-Related Matters

    • Small Business Relief. ASCs may be eligible for relief that is available to small businesses in response to the COVID-19 pandemic. Our team prepared this summary of the Small Business Relief in an earlier version of the Cares Act and is in the process of reviewing any changes to the proposal in the final bill.
    • Paid Time Off Under the Families First Coronavirus Response Act. The Families First Act mandates that employers with fewer than 500 employees provide two weeks of paid sick leave (subject to certain caps and in addition to any other leave already provided) for employees who are affected by COVID-19 and unable to work or telework. Such employers must provide an additional 10 weeks of Family and Medical Leave Act leave, paid at two-thirds the employee’s regular pay rate, subject to a cap. The legislation also provides payroll tax credits to offset the costs of providing paid leave, and provides certain exemptions for employers of healthcare workers and some flexibility for employers with 50 or fewer employees.
    • Frequently Asked Questions for US Employers. Like all US employers, ASC operators and management companies are struggling to cope with various issues arising from the COVID-19 pandemic that affect their workforces. For guidance on some of the most common questions, read our client alert “Coronavirus FAQs for US Employers.”

    Accreditation Survey Suspensions.

    • On March 4, 2020, CMS directed all accreditation agencies and state licensing agencies to suspend non-emergent survey inspections to allow inspectors to prioritize the most serious health and safety threats, such as infectious disease and abuse. On March 13, 2020, CMS issued additional FAQs on this suspension. The Joint Commission, the American Association for Accreditation of Ambulatory Surgery Facilities, the Accreditation Association for Ambulatory Health Care and the Healthcare Facilities Accreditation Program have each issued communications to their members that all routine re-survey activities are suspended. Emergent surveys will continue, including in response to complaints related to infection control and patient safety. Surveys for initial accreditation also may continue. All postponed surveys will resume once normal operations have restarted, and CMS has indicated that Medicare payment status will not be affected. Any centers with upcoming re-certification surveys should submit relevant applications so that the survey will be scheduled once normal operations resume.

    Relief for Facilities Participating in Quality Reporting Programs.

    • On March 22, 2020, CMS announced that it will grant “extreme and uncontrollable circumstances policy exceptions and extensions” from reporting requirements for clinicians, providers and facilities participating in Medicare quality reporting programs to ease the burden imposed by the COVID-19 pandemic. For example, CMS will not count data from January 1, 2020, through June 30, 2020, for performance or payment programs, and data does not need to be submitted to CMS for the first two quarters of 2020.
    Authors

    Dana Dombey

    Partner

    Miami

    Amanda Jester

    Partner

    Austin

    Adam J. Rogers

    Partner

    Miami

    Chelsea Rogers

    Partner

    Miami

    More insights

  • FTC, DOJ Issue Antitrust Statement on COVID-19 Response Collaborations

    ARTICLE / CLIENT ALERT

    FTC, DOJ Issue Antitrust Statement on COVID-19 Response Collaborations

    March 25, 2020

    Read time: 6 min

    Key takeaways
    Overview

    On March 24, 2020, the US Federal Trade Commission (FTC) and US Department of Justice (DOJ) issued a Joint Antitrust Statement Regarding COVID-19. In this statement, the FTC and DOJ recognize that public health efforts in response to the Coronavirus (COVID-19) require government and private cooperation. To address the speed at which companies and individuals must engage in COVID-19 response activities, the FTC and DOJ will respond to COVID-19-related requests for advisory opinions and business review letters within an expedited seven days of receipt of all information.

    In depth

    On March 24, 2020, the US Federal Trade Commission (FTC) and US Department of Justice (DOJ) issued a Joint Antitrust Statement Regarding COVID-19. In this statement, the FTC and DOJ recognize that public health efforts in response to the Coronavirus (COVID-19) require government and private cooperation. Many forms of pro-competitive collaborations do not violate the antitrust laws, as recognized in existing FTC/DOJ guidance, such as the Antitrust Guidelines for Collaborations Among Competitors and the Statements of Antitrust Enforcement Policy in Health Care. However, the FTC and DOJ state that they are prepared to pursue civil violations of the antitrust laws for agreements “between individuals and business to restrain competition through increased prices, lower wages, decreased output, or reduced quality as well as efforts by monopolists to use their market power to engage in exclusionary conduct.” DOJ also has the power to prosecute criminal violations of the antitrust laws.

    Companies and individuals considering coordinating conduct in response to COVID-19 should review, as a threshold question, the purpose of the proposed competitor collaboration. Pro-competitive purposes include increasing access to healthcare services or supplies, improving the quality of care and reducing unnecessary costs of healthcare. Anti-competitive purposes include decreasing output, access and quality, and increasing healthcare costs.

    The nature and extent of the parties’ combination of resources, intended pro-competitive efficiencies, and potential competitive effects of the collaboration in the relevant product and geographic markets in which the parties compete should also be considered. As this analysis often depends on all relevant facts and circumstances, the FTC has an existing advisory opinion process and the DOJ has an existing business review letter process for parties to request federal antitrust enforcement agency views on proposed conduct. Those processes can take many months after submission of all initial and follow-up requests for information, however.

    To address the speed at which companies and individuals must engage in COVID-19 response activities, the statement provides that DOJ and FTC staff will respond to COVID-19-related requests within an expedited seven days of receipt of all information. A successful review will provide a statement of the government’s present enforcement intention related to the proposed arrangement, and can therefore provide significant comfort, although it is not antitrust immunity.

    FTC/DOJ Guidance on Activity Unlikely to Raise Antitrust Concerns

    The following is an overview of the antitrust framework for several types of joint activities that individuals and business may undertake in response to COVID-19.

    Research and Development

    The agencies reiterate their prior guidance that “when firms collaborate on research and development this ‘efficiency-enhancing integration of economic activity’ is typically procompetitive.”

    Sharing General “Know-How” and Clinical Best Practices

    Parties may continue to share technical “know-how,” clinical best practices and other similar information to combat COVID-19. For example, healthcare providers may continue to collect and share clinical outcome data and suggested practice parameters to develop protocols or otherwise increase quality and efficiency.

    Joint Purchasing Arrangements

    The FTC and DOJ recognize that many joint purchasing arrangements among hospitals or other healthcare providers do not raise antitrust concerns as they are designed to achieve efficiencies (i.e., cost-savings) that should benefit consumers. An antitrust safety zone provides that the FTC and DOJ will not challenge, absent extraordinary circumstances, any joint purchasing arrangement among healthcare providers where two conditions are present:

    • The purchases account for less than 35% of the total sales of the purchased product or service in the relevant market.
    • The cost of the products and services purchased jointly accounts for less than 20% of the total revenues from all products or services sold by each competing participant in the joint purchasing arrangement.

    Emergency Measures and Government Collaboration

    If competitors are contemplating measures that may involve conduct that would be viewed as anti-competitive under normal circumstances, but which they believe is necessary to support the government’s COVID-19 efforts (for example, coordinating behavior to help healthcare providers receive critical supplies), the conduct still may be possible under certain emergency government powers. For example, both the Defense Production Act of 1950 and the Pandemic and All-Hazards Preparedness Act (PAHPA) provide antitrust immunity for agreements made under the supervision of, and in cooperation with, the federal government. The DOJ and FTC are ready to assist where parties are working with the Federal Emergency Management Agency, the US Department of Health and Human Services, or other government agencies to pursue such agreements.

    Parties also may petition the government or jointly engage in lobbying efforts under Noerr-Pennington. An example in the current circumstances may include “private industry meetings with the federal government to discuss strategies on responding to COVID-19” or to solicit the government to act. These rights to petition and lobby the government remain untouched in the current circumstances.

    Finally, the agencies stated that they will process filings expeditiously that are made under the National Cooperative Research and Production Act. This act applies to certain joint ventures for research and development or production, as well as standards development organizations. The act remains unaffected, but the agencies indicated that they will review submissions more quickly.

    Authors

    Ashley M. Fischer

    Partner

    Chicago

    Jon B. Dubrow

    Partner

    Washington, DC

    More insights

  • Disaster Relief Payments: The Simplest and Most Tax-Efficient Method to Assist Employees Impacted by COVID-19

    ARTICLE

    Disaster Relief Payments: The Simplest and Most Tax-Efficient Method to Assist Employees Impacted by COVID-19

    March 2020

    Read time: 1 min

    Key takeaways
    Overview

    Reproduced with permission from Copyright 2020 The Bureau of National Affairs, Inc. (800-372-1033) www.bloombergindustry.com.

    In depth
    Authors
    More insights

  • Disaster Relief Payments: Tax-Efficient Assistance to Employees Impacted by Covid-19

    ARTICLE

    Disaster Relief Payments: Tax-Efficient Assistance to Employees Impacted by Covid-19

    March 2020

    Read time: 1 min

    Key takeaways
    Overview

    Reproduced with permission from Copyright 2020 The Bureau of National Affairs, Inc. (800-372-1033) www.bloombergindustry.com.

    In depth
    Authors
    More insights

  • Economic Stabilization Fund Mitigates Losses in Germany

    ARTICLE

    Economic Stabilization Fund Mitigates Losses in Germany

    March 25, 2020

    Read time: 2 min

    Key takeaways
    Overview

    As part of the Coronavirus (COVID-19) legislative aid program, the German Federal Government released a draft legislative proposal for the establishment of an economic stabilization fund (Wirtschaftsstabilisierungsfonds) to the total amount of EUR 600 billion to mitigate the economic consequences caused by the Coronavirus and to stabilize German companies with a certain minimum size in terms of employees, turnover and/or balance sheet total.

    In this article published in Börsen-Zeitung, (Edition 59, Page 6), Prof. Dr. Wilhelm Haarmann, Renate Prinz, Daniel von Brevern and Andrea Stockhorst assess the proposal with regard to its measures and effectiveness by summarizing the respective support options, potential beneficiaries and the prerequisites and potential conditions to be met. The article also draws comparison to the actions taken by the federal republic during the financial crisis in 2008/2009, as the fund is now adopted in the same regulatory framework.

    In depth
    Authors
    More insights